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A B S T R A C T
Background
Previously, we demonstrated that hypofibrinolysis, a decreased capacity to dissolve a blood
clot as measured with an overall clot lysis assay, increases the risk of venous thrombosis. Here,
we investigated the combined effect of hypofibrinolysis with established risk factors associated
with hypercoagulability.
Methods and Findings
Fibrinolytic potential was determined with a plasma-based clot lysis assay in 2,090 patients
with venous thrombosis and 2,564 control participants between 18 and 70 y of age enrolled in
the Multiple Environmental and Genetic Assessment (MEGA) of risk factors for venous
thrombosis study, a population-based case-control study on venous thrombosis. Participants
completed a standardized questionnaire on acquired risk factors.
Hypofibrinolysis alone, i.e., clot lysis time (CLT) in the fourth quartile (longest CLT) (in absence
of the other risk factor of interest) increased thrombosis risk about 2-fold relative to individuals
with CLT in the first quartile (shortest CLT). Oral contraceptive use in women with CLT in the
first quartile gave an odds ratio (OR) of 2.6 (95% confidence interval [CI] 1.6 to 4.0), while
women with hypofibrinolysis who used oral contraceptives had an over 20-fold increased risk
of venous thrombosis (OR 21.8, 95% CI 10.2 to 46.7). For immobilization alone the OR was 4.3
(95% CI 3.2 to 5.8) and immobilization with hypofibrinolysis increased the risk 10.3-fold (95% CI
7.7 to 13.8). Factor V Leiden alone increased the risk 3.5-fold (95% CI 2.3 to 5.5), and
hypofibrinolysis in factor V Leiden carriers gave an OR of 8.1 (95% CI 5.3 to 12.3). The
combination of hypofibrinolysis and the prothrombin 20210A mutation did not synergistically
increase the risk. All ORs and 95% CIs presented are relative to individuals with CLT in the first
quartile and without the other risk factor of interest.
Conclusions
The combination of hypofibrinolysis with oral contraceptive use, immobilization, or factor V
Leiden results in a risk of venous thrombosis that exceeds the sum of the individual risks.
The Editors’ Summary of this article follows the references.
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Introduction
A hypercoagulable state, an increased capacity to form
thrombin, is known to be associated with an increased risk of
venous thrombosis [1]. However, the role of the fibrinolytic
system in the development of venous thrombosis has not yet
been extensively investigated.
We have shown that reduced fibrinolytic potential, as
measured by a plasma-based clot lysis assay, increases the risk
of a first deep vein thrombosis (DVT) [2]. An almost 2-fold
increased risk of DVT was found in individuals with clot lysis
times (CLTs) above the 90th percentile of the values found in
control participants compared with individuals with CLTs
below this cut-off point.
Venous thrombosis is a multicausal disease, and several
genetic and acquired risk factors associated with venous
thrombosis have already been described [1]. The occurrence
of multiple risk factors within a single patient may be
associated with a risk of thrombosis that exceeds the sum of
the individual risks. Such an increase is, for example, found in
women with the factor V Leiden mutation who also use oral
contraceptives. While carriers of the factor V Leiden
mutation have a 5-fold increased risk of venous thrombosis,
and oral contraceptive use increases the risk about 3-fold, the
combination of these risk factors leads to a 20- to 30-fold
increased risk (reviewed in [3]). A synergistic effect is also
found for the combination of the factor V Leiden mutation
and malignancy or air travel [4,5]. We hypothesized that the
combination of hypofibrinolysis and hypercoagulability
would synergistically enhance the risk of venous thrombosis.
This hypothesis was investigated in the Multiple Environ-
mental and Genetic Assessment (MEGA) of risk factors for
venous thrombosis study, which is a large population-based
case-control study on venous thrombosis. First, we studied
hypofibrinolysis as a risk factor for thrombosis, and inves-
tigated the joint effect of hypofibrinolysis and several
established risk factors for venous thrombosis. Second, we
studied the influence of several genetic and acquired factors
on the outcome of the clot lysis assay.
Methods
Study Design
The design of the MEGA study has been described
previously [4]. Between March 1999 and May 2002, consec-
utive patients aged 18 to 70 y, with a first DVT of the leg or a
first pulmonary embolism (PE), were identified at six anti-
coagulation clinics in The Netherlands. In these clinics, the
anticoagulant therapy of all patients in a well-defined
geographical area is monitored, which gave us the oppor-
tunity to identify consecutive and unselected patients with
venous thrombosis.
Partners of participating patients were invited to take part
as control participants. From January 2002 to September
2004, an additional control group was selected from the same
area by random digit dialing using the Mitofsky-Waksberg
method [6] and was frequency matched to the patients for age
and sex. This matching was on group level in which random
controls were selected in numbers proportional to the
number of patients within strata of sex and 5-y age groups.
Patients or control participants with severe psychiatric
problems or those who could not speak Dutch were excluded.
For the MEGA study, 4,131 patients were eligible. Of those
patients, 194 died soon after the venous thrombosis. Of the
remaining 3,937 patients, 51 were in the end stage of a disease
and 629 were unable or refused to participate, leaving 3,257
patients in the study who filled in a questionnaire (83%). Of
the total of 3,257 patients of the MEGA study, 2,360 had an
eligible partner. One partner died soon after the request for
participation and, of the remaining 2,359 partners, 1,908
participated (81%). Of the nonparticipating partners, 15
were in the end-stage of a disease and 436 refused, were
unable to participate, or could not be located. Of the 4,350
eligible random digit dialing control participants, four died
before they were able to participate, 15 were in the end stage
of a disease, and 1,331 refused to participate or could not be
located, leaving 3,000 participants in the study (69%).
All participants signed a written informed consent form.
Approval for this study was obtained from the Medical Ethics
Committee of the Leiden University Medical Center, Leiden,
The Netherlands.
Validation of Thrombosis Diagnosis
Written informed consent to obtain medical records was
given by 95% of the patients. Information regarding the
diagnostic procedure was obtained via hospital records and
general practitioners. For 10% of these patients the
information regarding the diagnostic procedure could not
be obtained. A PE was considered ‘‘definite’’ when diagnosed
with a high-probability ventilation-perfusion scan (VQ scan),
positive spiral computed tomography (CT), or angiogram. A
PE was considered ‘‘probable’’ when diagnosed with a low- or
intermediate-probability VQ scan, inconclusive spiral CT, or
angiogram. A deep venous thrombosis was considered
definite when a (Doppler) ultrasound showed the presence
of a thrombus in the deep veins. When no information
regarding the diagnostic procedure was available or when a
patient was registered at the anticoagulation clinic with a
different or additional diagnosis to the one that had been
objectively confirmed, the diagnosis by which the patient was
registered at the anticoagulation clinic was added. A
registration of a PE was considered probable while a DVT
registration was considered definite. Only those patients were
included in the study when their diagnosis was definite or
probable. Of those patients in whom diagnostic information
was available, only 2% was excluded as they did not have a
venous thrombotic event according to the medical records.
Data Collection and Current Analysis
All participants were asked to complete a standardized
questionnaire on acquired risk factors for venous thrombosis,
such as surgery, plaster cast, confinement to bed, injury, oral
contraceptive use, hormonal replacement therapy, preg-
nancy, and malignancy. Body mass index (BMI in kg/m2) was
calculated from self-reported weight and height. All items in
the questionnaire referred to the period before the index
date. The date of diagnosis of thrombosis as reported by the
participant was used as the index date for the patients. For
the control participants, the date they filled in the ques-
tionnaire was used as index date. Idiopathic venous throm-
bosis was defined as venous thrombosis in patients who had
never had malignancies and without surgery, injury, plaster
cast, or confinement to bed in the year prior to the
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thrombosis or oral contraceptive use or hormone replace-
ment therapy at the time of the event.
When participants were unable to fill in the questionnaire,
questions were asked by telephone, using a standardized
mini-questionnaire. Three months after discontinuation of
the anticoagulant therapy, a blood sample was taken from
patients and participating partners in the anticoagulation
clinic. In patients who received prolonged anticoagulant
therapy (.1 y), blood was drawn 1 y after the event. The
random control participants were invited to the clinic for a
blood draw after returning their questionnaire. All partic-
ipants were interviewed regarding current anticoagulant use.
In the current analyses only patients who had their blood
drawn were included (n¼ 2,420). Users of oral anticoagulants
at time of blood draw were excluded (n ¼ 290) as well as 38
patients who, according to the medical records did not have
venous thrombosis, leaving 2,092 patients available for this
study.
Of these 2,092 patients, 1,328 partner controls participated
in the MEGA study. Blood was drawn of 1,138 partner
controls and seven were excluded because they used anti-
coagulants, leaving 1,131 partner controls available for this
study. Of the 3,000 random control participants, 1,460 had
their blood drawn and 1,440 were not using oral anti-
coagulants.
Blood Collection and Laboratory Analysis
Blood samples were drawn into vacuum tubes containing
0.106 M trisodium citrate. Plasma was obtained by centrifu-
gation at 2,000g for 10 min at room temperature and stored
in aliquots at 80 8C. Samples that were not previously
thawed were used for this study. Lysis of a tissue factor–
induced clot by exogenous tissue-type plasminogen activator
(t-PA) was studied by monitoring changes in turbidity during
clot formation and subsequent lysis as described previously
[2]. In short, 50 ll plasma was pipetted in a 96-well microtiter
plate. Subsequently, 50 ll of a mixture containing phospho-
lipid vesicles (40% L-a-dioleoylphosphatidylcholine, 20% L-
a-dioleoylphosphatidylserine, and 40% L-a-dioleoylphospha-
tidylethanolamine, final concentration 10 lM), t-PA (final
concentration 56 ng/ml), tissue factor (final dilution 1:1000),
and CaCl2 (final concentration 17 mM), diluted in HEPES
buffer (25 mM HEPES [N-2-hydroxytethylpiperazine-N ’-2-
ethanesulfonic acid], 137 mM NaCl, 3.5 mM KCl, 3 mM CaCl2,
0.1% bovine serum albumin, pH 7.4), was added using a
multichannel pipette. After thorough mixing, the plate was
incubated at 37 8C in a Spectramax 340 kinetic microplate
reader (Molecular Devices Corporation), and the optical
density at 405 nm was monitored every 20 s, resulting in a
clot-lysis turbidity profile. The CLT was derived from this
clot-lysis profile and defined as the time (minutes) from the
midpoint of the clear to maximum turbid transition,
representing clot formation, to the midpoint of the max-
imum turbid to clear transition, representing the lysis of the
clot. The intra-assay coefficient of variation was 5.5% (n¼ 99)
and the inter-assay coefficient of variation was 6.6% (n¼ 90).
A detailed description of DNA extraction and DNA analysis
for the factor V Leiden (G1691A) mutation and the
prothrombin (G20210A) mutation in the MEGA study has
been published previously [4].
Of two patients (without participating partner), three
partners, and four random control participants, no citrated
plasma was available or the CLT could not be measured as the
plasma was too turbid.
The DNA analyses and the clot lysis assays were performed
by staff who had no knowledge of whether the sample was
from a patient or a control participant.
Statistical Analysis
We investigated whether elevated CLT is a risk factor for
venous thrombosis by calculating odds ratios (ORs), as an
approximation of relative risks, and 95% confidence intervals
(CIs). CLTs were grouped into quartiles or deciles based on
the distribution among all control participants. The lowest
quartile or decile was taken as the reference group. ORs
adjusted for age (continuous) and sex (categorical) (ORadj)
were calculated using multivariate logistic regression. Anal-
yses in subgroups by sex were adjusted only for age. Analyses
in subgroups of age were adjusted for sex and for age
(continuous) within each stratum of age. Adjustment for age
as a dummy variable (five categories) did not change the
results compared to models with age as a continuous
covariate, and the latter adjustment is presented for all
analyses.
A patient and his or her partner control may be more
similar than a random pair selected from the population
would be, e.g., on (measured and unmeasured) lifestyle factors
that could influence fibrinolytic potential. Therefore, we
performed conditional logistic regression to adjust for all
matching factors in the analyses with partners as control
group [5], including 1,128 patient-partner pairs. In the
analyses with the random control group, unconditional
logistic regression including all patients and random control
participants were performed. To obtain a final estimate,
results of unmatched and matched analyses were pooled. As
both estimates used the same subset of 1,128 patients, the
estimates are correlated. Therefore these estimates were
pooled using analyses taking this correlation into account [7].
When subgroup analyses were performed on men and
women separately, only an unmatched analysis with the
random control group was performed, as a matched analysis
was not possible because the patient and matched control
were nearly always of the opposite sex.
We assessed the joint effect of quartiles of CLT with other
risk factors for venous thrombosis by calculating ORs.
Participants in the first quartile of CLT and without the
other risk factor of interest were used as the reference
category, and dummy variables were used for the seven other
categories.
To study the association between clotting abnormalities
and acquired (risk) factors with CLT in the control group
(partners and random controls), mean CLTs of different
groups were calculated and confidence intervals were con-
structed for the difference based on a t-distribution. The
association between age and BMI with CLT was assessed using
linear regression. Linear regression was also used to
determine the association between the time interval between
the thrombotic event and blood draw and CLT in the
patients. Longer CLTs in those with a small time interval than
in those with a large time interval could indicate that
increased CLT is rather an acute-phase reaction than a risk
factor for venous thrombosis.
Cases and controls with missing data were excluded in the
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analyses. SAS 9.1 (SAS Institute) was used for all statistical
analyses.
Results
In this study, 2,090 patients, 1,128 partner controls, and
1,436 random controls were included. Mean age at time of
blood draw of patients was 49 y (range 19–71y) and mean age
of all control participants was 48 y (range 18–71 y). Of the
patient group 926 participants (44%) were men, whereas in
the control group 1,226 participants (48%) were men. Of the
2,090 patients, 650 were diagnosed with an isolated PE, 1,245
with an isolated DVT of the leg, and 195 of all the patients
were diagnosed with both a PE and a DVT of the leg.
Hypofibrinolysis as a Risk Factor for Venous Thrombosis
The association between CLT and the risk of venous
thrombosis is shown in Figure 1. Using deciles of CLT based
on the values found in all control participants, we found a
clear dose-response relation between CLT and the risk of
venous thrombosis. The ORadj for individuals in the tenth
decile of CLT compared with individuals in the first decile
was 2.9 (95% CI 2.2 to 3.8). In Table 1 the risk of venous
thrombosis is presented in quartiles. Individuals with
hypofibrinolysis, i.e., CLTs in the highest quartile, had an
increased relative risk of venous thrombosis of 2.4 (95% CI
2.0 to 2.8) compared with individuals in the lowest quartile of
CLT. Adjustment for age and sex did not change this result
(ORadj 2.4, 95% CI 2.0 to 2.8). Using only the random control
group yielded an ORadj of 2.5 (95% CI 2.1 to 3.1), and the
matched analysis with only partner controls resulted in a
similar ORadj of 2.0 (95% CI 1.5 to 2.6) for those with
hypofibrinolysis.
Hypofibrinolysis was associated with a 3.2-fold increased
risk of a simultaneous DVT of the leg and a PE (ORadj 3.2,
95% CI 1.9 to 5.3) (Table 2). Hypofibrinolysis conferred a 2.1-
fold increased risk of an isolated PE (ORadj 2.1, 95% CI 1.6 to
2.8). For an isolated DVT of the leg an ORadj of 2.6 was found
(95% CI 2.1 to 3.2).
The relative risk of venous thrombosis in individuals with
hypofibrinolysis was most pronounced in women below age
50 y (ORadj 3.2, 95% CI 2.2 to 4.6) (Table 3). As blood of these
women was drawn after the event and most patients but not
the control participants had ceased oral contraceptive use
before time of blood draw, this difference could have
influenced the risk found in younger women. For that reason
we also calculated the risk in women below age 50 y who did
not use oral contraceptives at time of the index date and still
did not use oral contraceptives at time of blood draw. In
those women, an ORadj of 2.3 (95% CI 1.3 to 4.1) was found. In
women over age 50 y, the ORadj was 2.8 (95% CI 1.7 to 4.6).
The relative risk in men below age 50 y with hypofibrinolysis
was slightly lower (ORadj 2.2, 95% CI 1.4 to 3.5) than in men
over age 50 y (ORadj 2.8, 95% CI 1.8 to 4.3).
The risk of idiopathic thrombosis in those with hypofi-
brinolysis was approximately 3-fold increased (ORadj 3.1, 95%
CI 2.2 to 4.4).
Hypofibrinolysis in Combination with Other Established
Risk Factors
Table 4 shows the risk of venous thrombosis for individuals
with hypofibrinolysis (i.e., the highest quartile of CLT) in
combination with established risk factors. The reference
group is the group with the lowest CLTs (i.e., in the first
quartile) and in absence of the other risk factor. To study the
joint effect of hypofibrinolysis and oral contraceptive use on
venous thrombosis, only women below the age of 50 y were
included. Women with the lowest CLTs who were taking oral
contraceptives had a 2.6-fold increased risk of venous
thrombosis (ORadj 2.6, 95% CI 1.6 to 4.0) compared with
women with the lowest CLTs who did not take oral contra-
ceptives. In those with the highest CLTs who did not take oral
contraceptives, an ORadj of 1.9 (95% CI 1.1 to 3.3) was found
Figure 1. Risk of Venous Thrombosis for Deciles of Clot Lysis Time
The odds ratios are adjusted for age and sex. Error bars, 95% CI; nc,
number of control participants (all); np, number of patients; Ref.,
reference category.
doi:10.1371/journal.pmed.0050097.g001
Table 1. Relative Risk of Venous Thrombosis According to Quartiles of Clot Lysis Time
CLT Quartile
1 (Reference)
CLT Quartile 2 CLT Quartile 3 CLT Quartile 4
Lysis time at cut-off (min) — 57.9 65.6 75.9
Cases (n) 340 491 558 701
Controls (all, n) 641 641 641 641
OR (95% CI) 1 1.5 (1.3 to 1.8) 1.8 (1.5 to 2.2) 2.4 (2.0 to 2.8)
ORadj (95% CI) 1 1.5 (1.3 to 1.8) 1.8 (1.5 to 2.2) 2.4 (2.0 to 2.8)
OR, crude odds ratio; ORadj, odds ratio adjusted for age and sex.
doi:10.1371/journal.pmed.0050097.t001
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compared with the reference group. The combination of
hypofibrinolysis and oral contraceptive use gave a 22-fold
increased risk (ORadj 21.8, 95% CI 10.2 to 46.7).
The risk of venous thrombosis in individuals with a
combination of hypofibrinolysis and immobilization (defined
as either plaster cast, confinement to bed for more than 4 d, or
surgery) was also assessed (Table 4). The ORadj for individuals
with hypofibrinolysis and no immobilization was 2.4 (95% CI
1.9 to 2.9), and for individuals with CLT in the lowest quartile
who were immobilized it was 4.3 (95% CI 3.2 to 5.8). Those
who were immobilized and who had hypofibrinolysis had a 10-
fold increased risk of venous thrombosis compared with
individuals without these risk factors (ORadj 10.3; 95% CI 7.7
to 13.8). When plaster cast, confinement to bed, and surgery
were analyzed separately in combination with hypofibrinol-
ysis, the same trends were found as when these three risk
factors were combined into one variable (unpublished data).
In individuals with hypofibrinolysis without the factor V
Leiden mutation an ORadj of 2.4 (95% CI 2.0 to 2.9) was found
(Table 4). Carriers of the factor V Leiden mutation with the
lowest CLTs had a risk of venous thrombosis that was 3.5-fold
(95% CI 2.3 to 5.5) increased. The risk of venous thrombosis
increased 8.1-fold (95% CI 5.3 to 12.3) for individuals with
hypofibrinolysis and the factor V Leiden mutation. Similar
analyses for the prothrombin 20210A mutation gave an ORadj
of 2.3 (95% CI 2.0 to 2.8) for hypofibrinolysis only, 2.4 (95%
CI 0.7 to 8.1) for the prothrombin 20210A mutation only, and
4.4 (95% CI 2.5 to 7.6) for the combination. When patients
with pulmonary emboli were excluded, the same trend in
risks was found, but somewhat higher ORs were found for the
risk of factor V Leiden alone and the combination of factor V
Leiden with hypofibrinolysis (unpublished data).
In each of the above analyses of combinations of risk
factors, the risks of venous thrombosis in the 2nd and 3rd
quartile of CLT (in the presence or absence of the other risk
factor) showed a consistent trend. With each increasing
quartile of CLT, the risk of venous thrombosis also increased
(unpublished data).
Determinants of Clot Lysis Time
All control participants were used to study genetic and
acquired factors as determinants of CLTs (Table 5). Mean
CLT in the control group was 69.8 min (5th to 95th
percentile, 49.4 to 105.1). CLT increased with age (3.1 min
Table 2. Relative Risk of Venous Thrombosis According to Quartiles of Clot Lysis Time in Subgroups of Venous Thrombosis
Diagnosis CLT Quartile 1
(Reference)
CLT Quartile 2 CLT Quartile 3 CLT Quartile 4
DVT of the leg Cases (n) 200 285 340 420
Controls (all, n) 542 545 504 514
ORadj (95% CI) 1 1.5 (1.2 to 1.8) 2.1 (1.6 to 2.6) 2.6 (2.1 to 3.2)
DVT of the leg þ PE Cases (n) 24 50 53 68
Controls (all, n) 428 407 339 358
ORadj (95% CI) 1 2.1 (1.2 to 3.4) 2.6 (1.6 to 4.4) 3.2 (1.9 to 5.3)
PE Cases (n) 116 156 165 213
Controls (all, n) 481 467 426 425
ORadj (95% CI) 1 1.4 (1.1 to 1.8) 1.6 (1.2 to 2.1) 2.1 (1.6 to 2.8)
ORadj, odds ratio adjusted for age and sex.
doi:10.1371/journal.pmed.0050097.t002
Table 3. Relative Risk of Venous Thrombosis According to Quartiles of Clot Lysis Time
Group CLT Quartile 1 (Reference) CLT Quartile 2 CLT Quartile 3 CLT Quartile 4
Women ,50 y Cases (n) 175 219 172 152
Random controls (n) 186 131 85 51
ORadj (95% CI) 1 1.8 (1.3 to 2.4) 2.2 (1.5 to 3.0) 3.2 (2.2 to 4.6)
Women ,50 y not taking oral contraceptivesa Cases (n) 47 49 50 43
Random controls (n) 92 74 56 41
ORadj (95% CI) 1 1.4 (0.8 to 2.3) 1.9 (1.1 to 3.2) 2.3 (1.3 to 4.1)
Women 50 y Cases (n) 35 85 126 200
Random controls (n) 56 72 79 117
ORadj (95% CI) 1 1.9 (1.1 to 3.2) 2.6 (1.6 to 4.4) 2.8 (1.7 to 4.6)
Men ,50 y Cases (n) 53 65 98 113
Random controls (n) 91 90 65 80
ORadj (95% CI) 1 1.2 (0.7 to 1.9) 2.4 (1.5 to 3.9) 2.2 (1.4 to 3.5)
Men 50 y Cases (n) 77 122 162 236
Random controls (n) 72 96 85 80
ORadj (95% CI) 1 1.2 (0.8 to 1.8) 1.8 (1.2 to 2.7) 2.8 (1.8 to 4.3)
aAt index date and at time of blood draw.
ORadj, odds ratio adjusted for age.
doi:10.1371/journal.pmed.0050097.t003
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per decade, 95% CI 2.6 to 3.6). In men a plateau was reached
at age 60. Overall, mean CLT in men (70.9 min, 5th to 95th
percentile 50.2 to 106.2) was slightly higher than mean CLT in
women (68.7 min, 5th to 95th percentile 48.6 to 103.0),
although the difference was small (2.2 min, 95% CI 0.7 to 3.7).
CLTs substantially increased with increasing BMI. The
increase in CLT per 1 kg/m2 increase in BMI was 2.0 min
(95% CI 1.8 to 2.1). When we used conventional classification
of BMI as underweight (,20 kg/m2), normal (20–24 kg/m2),
overweight (BMI 25–29 kg/m2), and obese (BMI  30 kg/m2),
mean CLT was 58.0 min (5th to 95th percentile 44.8 to 73.2)
in those who were underweight, 63.5 min (5th to 95th
percentile 48.0–84.3) in those who had normal BMI, 73.8 min
(5th to 95th percentile 52.3 to 109.2) in individuals who were
overweight, and 83.9 min (5th to 95th percentile 56.3 to 131.0)
in obese individuals. In women not using oral contraceptives,
the mean CLT was 5.4 min longer (95% CI 3.0 to 7.7) than in
women taking oral contraceptives. Diabetes was associated
with a 17% increase in CLT (11.7 min, 95% CI 7.2 to 16.2)
compared with individuals without diabetes. In carriers of the
prothrombin 20210A mutation, mean CLT was 12% in-
creased (8.1 min, 95% CI 2.3 to 13.8) compared with
noncarriers. Carriers of the factor V Leiden mutation had
similar CLTs to noncarriers (difference 2.1 min, 95% CI1.2
to 5.5).
It is known that BMI is associated with plasminogen
activator inhibitor-1 (PAI-1) levels [8] and the prothrombin
20210A mutation was found to be associated with increased
thrombin-activatable fibrinolysis inhibitor (TAFI) activation
in a study that used a clot lysis assay similar to that used in
our study [9]. We adjusted the ORs in Table 2 for BMI and the
prothrombin 20210A mutation to see whether the increased
risk of venous thrombosis in individuals with hypofibrinolysis
could (in part) be explained by the increase in these
fibrinolytic factors. Adjustment for BMI and the prothrombin
20210A mutation only moderately decreased the association
between hypofibrinolysis and venous thrombosis (ORs [95%
CIs] for quartile 2, 3, and 4: 1.4 [1.2 to 1.7], 1.6 [1.3 to 1.9], and
1.8 [1.5 to 2.1]).
Within the patient group, we studied the association
between the time interval between the event and the day of
blood draw and CLT. The 5th to 95th percentile of this time
interval was 188–502 d, with a mean of 318 d (median 301 d).
No association was found between the time interval and CLT
(0.004 min decrease in CLT/d increase; 95% CI 0.006 to
0.014).
Discussion
In this large population-based case-control study, including
over 4,500 individuals, we have shown that decreased
fibrinolytic activity, as measured with a plasma-based assay,
was associated with an increased risk of a first venous
thrombosis. The combination of hypofibrinolysis with im-
mobilization, factor V Leiden, and especially oral contra-
ceptive use, resulted in high relative risks. CLTs were
associated with age, BMI, diabetes, oral contraceptive use,
and the prothrombin 20210A mutation.
The risk of venous thrombosis for individuals with
hypofibrinolysis was 2.4-fold increased compared with those
with CLTs in the first quartile. Furthermore, there was a clear
dose-response relation between CLT and the risk of venous
thrombosis. Our findings support the results of the Leiden
Thrombophilia Study (LETS) [2]. In this case-control study,
CLTs above the 90th percentile of the levels found in the
control group were associated with an almost 2-fold increased
risk of venous thrombosis.
Because hypercoagulation is a well-established risk factor
for venous thrombosis [1,4], we hypothesized that hyper-
coagulation and hypofibrinolysis have synergistic effects on
venous thrombosis. First, we studied the risk of venous
thrombosis in individuals with hypofibrinolysis combined
Table 4. Hypofibrinolysis, Presence of Established Genetic and Acquired Risk Factors, and Relative Risk of Venous Thrombosis
Risk Factor Present? Quartile of CLT Cases (n) Controls (n)a ORadj (95% CI)
Oral contraceptive use at index dateb,c No 1 50 93 1 (reference)
4 44 42 1.9 (1.1 to 3.3)
Yes 1 125 93 2.6 (1.6 to 4.0)
4 107 9 21.8 (10.2 to 46.7)
Immobilizationc,d No 1 194 550 1 (reference)
4 415 550 2.4 (1.9 to 2.9)
Yes 1 142 88 4.3 (3.2 to 5.8)
4 282 85 10.3 (7.7 to 13.8)
Factor V Leiden No 1 288 605 1 (reference.)
4 590 608 2.4 (2.0 to 2.9)
Yes 1 52 36 3.5 (2.3 to 5.5)
4 111 33 8.1 (5.3 to 12.3)
Prothrombin 20210A No 1 332 636 1 (reference)
4 661 620 2.3 (2.0 to 2.8)
Yes 1 8 5 2.4 (0.7 to 8.1)
4 40 21 4.4 (2.5 to 7.6)
aIn analyses on hypofibrinolysis and oral contraceptive use, random controls are used. In the other analyses all controls are used.
bAnalyses in women below the age of 50 y.
cInformation about oral contraceptive use was unavailable for one patient and information about immobilization was unavailable for eight cases and nine control participants.
dImmobilization was defined as plaster cast, confinement to bed for more than 4 d, or surgery.
ORadj, odds ratio adjusted for age (in analyses on hypofibrinolysis and oral contraceptive use) or age and sex (in other analyses).
doi:10.1371/journal.pmed.0050097.t004
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with established acquired risk factors. We found a 22-fold
increase in risk in women with hypofibrinolysis who were
taking oral contraceptives compared with women with
neither risk factor. Although the thrombosis risk associated
with oral contraceptive use is well known, the mechanisms
behind the increased risk of venous thrombosis are still
incompletely elucidated [3]. Oral contraceptive use induces
complex changes in the hemostatic system, including in-
creased levels of several procoagulant factors, reduction in
levels of anticoagulant factors, and activated protein C
resistance. In addition, oral contraceptive use results in
complex changes in fibrinolytic variables suggestive of
increased fibrinolytic capacity. However, the net effect of
these changes appears to be prothrombotic. The combination
of oral contraceptive use and factor V Leiden was previously
shown to result in a thrombosis risk larger than the sum of
the individual risks (reviewed in [3]). This effect is presumably
due to further exacerbation of thrombin-generating capacity
induced by both risk factors. The substantially increased risk
associated with hypofibrinolysis and oral contraceptive use
possibly relates to a concomitant presence of excessive
thrombin-generating capacity and defective clot breakdown.
The combination of immobilization (confinement to bed,
surgery, or plaster cast) and hypofibrinolysis resulted in a
synergistic effect, possibly via a similar mechanism because
immobilization leads to an increase of thrombin formation.
The increased risk of venous thrombosis during stasis may be
caused by endothelial cell activation and expression of P-
selectin, allowing tissue factor–bearing microvesicles to ini-
tiate coagulation and thrombosis [10]. Furthermore, increased
thrombin generation occurs after surgery, as demonstrated,
for example, by elevated levels of thrombin–antithrombin
complexes [11,12]. Although no other studies have investigated
the combined risk of immobilization and hypofibrinolysis, in a
review it was concluded that there was some evidence for an
association between decreased fibrinolytic potential (meas-
ured using different assays to the one used in the present study)
and postoperative thrombosis [13]. Furthermore, it is found
that, among hospitalized patients, the prevalence of asympto-
matic thrombi is high, up to about 40% (reviewed in [14]).
Although most asymptomatic thrombi resolve without causing
clinical consequences, it is plausible that those individuals with
a decreased capacity to remove these thrombi have a higher
risk of eventually developing a symptomatic venous thrombo-
sis. Similarly, the risk of an unprovoked (idiopathic) thrombo-
sis was also increased in individuals with hypofibrinolysis,
which may be explained by defective breakdown of asympto-
matic thrombi, as 1% of a healthy population was found to
have such an asymptomatic thrombus [15].
Second, we evaluated the effect of hypofibrinolysis in
combination with established genetic risk factors, i.e., factor
V Leiden or the prothrombin 20210A mutation. The joint
presence of factor V Leiden and hypofibrinolysis resulted in a
large increase in risk of DVT. Individuals with both factor V
Leiden and hypofibrinolysis had an 8.1-fold increased risk,
compared with the absence of both risk factors. This joint
effect can also be explained by the presence of both an
increased procoagulant state and a decreased fibrinolytic
potential.
The combination of hypofibrinolysis and the prothrombin
20210A mutation did not lead to a large increase in risk. A
difficulty in evaluating the combination of these two risk
Table 5. Clot Lysis Times in All Control Participants
Group Subgroup Participants (n) CLT, Mean (5th to 95th Percentile)
Age at blood draw (y), men All 1,226 70.9 (50.2 to 106.2)
18–29 96 63.6 (44.5 to 98.8)
30–39 228 68.1 (49.5 to 102.9)
40–49 286 72.9 (52.5 to 106.5)
50–59 345 73.8 (50.5 to 108.3)
60–71 271 70.2 (50.0 to 110.4)
Age at blood draw (y), women All 1,338 68.7 (48.6 to 103.0)
18–29 117 57.7 (44.5 to 73.8)
30–39 242 61.9 (47.1 to 81.9)
40–49 331 66.2 (47.9 to 100.3)
50–59 410 73.9 (52.0 to 114.2)
60–71 238 75.6 (52.4 to 110.8)
Use of oral contraceptives in women aged ,50 y Yes 266 60.0 (46.2 to 76.3)
No 424 65.3 (48.2 to 96.3)
Diabetesa Yes 71 81.1 (54.2 to 140.7)
No 2,389 69.3 (49.3 to 102.5)
BMI (kg/m2)b ,20 119 58.0 (44.8 to 73.2)
20–24 1,117 63.5 (48.0 to 84.3)
25–29 949 73.8 (52.3 to 109.2)
30 312 83.9 (56.3 to 131.0)
Factor V Leiden mutation AA or AG 132 71.8 (48.5 to 118.2)
GG 2,432 69.7 (49.4 to 104.0)
Prothrombin 20210A mutation AG 43 77.7 (54.5 to 124.9)
GG 2,521 69.6 (49.4 to 104.9)
aInformation about diabetes was unavailable for 95 control participants.
bInformation about BMI was unavailable for 67 control participants.
doi:10.1371/journal.pmed.0050097.t005
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factors is the apparent effect of prothrombin 20210A on
CLT. In accordance with results previously reported [9], we
found that individuals with the prothrombin 20210A muta-
tion had increased CLTs, conceivably related to increased
activation of TAFI.
We found shorter CLTs in women using oral contra-
ceptives compared with women not taking oral contra-
ceptives. This is in contrast with the results of a crossover
study showing no difference in CLT before and during oral
contraceptive use [16]. In that study, t-PA activity, plasmi-
nogen, and plasmin-a2-antiplasmin complexes were increased
during oral contraceptive use, and levels of PAI-1 antigen and
activity and t-PA antigen were decreased. It was suggested
that this increased fibrinolytic activity is counteracted by the
increased TAFI levels that were also found. However, a direct
comparison of the studies is complicated, because the CLT
assays used were slightly different. In the crossover study, the
plasma was clotted with thrombin and t-PA, while in our assay
tissue factor and t-PA is used.
We found a positive relation between BMI and CLT and
increased CLTs in individuals with diabetes. It is plausible
that PAI-1 plays an important role in these associations, as it
is known that PAI-1 is overexpressed in patients with diabetes
and obesity (reviewed in [8]).
In our previous study, we showed that the risk of venous
thrombosis in individuals with hypofibrinolysis as measured
with our clot lysis assay did not disappear after adjustment
for several coagulation factors shown to influence CLTs in
the control population [2]. This result suggests that the CLTs
are mostly determined by fibrinolytic factors. It is also
supported by the association between BMI and CLT and the
increased CLTs in individuals with diabetes and those with
the prothrombin 20210A mutation. Which fibrinolytic factor
or which combination of factors is important for this
increased risk is yet to be investigated.
A drawback of using case-control studies for finding
associations between the risk of venous thrombosis and blood
parameters is that the blood of the patients is drawn after the
thrombotic event. In this way decreased fibrinolysis could be
a consequence of the disease rather than a cause. However,
when CLT would increase as a result of the event, one would
expect such an acute-phase effect to attenuate with time after
the thrombotic event. In this study no relation was found
between CLT and the number of days between the event and
the blood draw.
We conclude that the risk of venous thrombosis is
increased in individuals with decreased fibrinolytic potential,
as measured by an overall plasma-based assay. The combina-
tion of hypofibrinolysis with established genetic and acquired
risk factors associated with hypercoagulation has a synergistic
effect on the thrombosis risk. This joint effect is observed in
individuals with hypofibrinolysis who use oral contraceptives,
are immobilized, or are carriers of the factor V Leiden
mutation, but not in patients who carry the prothrombin
20210A mutation.
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Editors’ Summary
Background.When a blood vessel is injured, proteins in the blood called
clotting factors ‘‘coagulate’’ (solidify) the blood at the injury site. The
resultant clot (thrombus) plugs the wound and prevents blood loss.
When the injury has healed, other proteins dissolve the clot, a process
called ‘‘fibrinolysis.’’ Sometimes, however, a thrombus develops inside
an undamaged blood vessel and partly or completely blocks the blood
flow. A clot that occurs in one of the veins (vessels that take the blood to
the heart) deep within the body (usually in the leg) is a deep vein
thrombosis (DVT). Some DVTs have no symptoms; others cause pain,
swelling, and tenderness in one leg. They are usually treated with
heparin and warfarin, anticoagulant drugs that stop the clot growing. If
left untreated, part of the clot (an embolus) can break off and travel to
the lungs, where it can cause a life-threatening condition called a
pulmonary embolism (PE).
Why Was This Study Done? Most people are very unlikely to develop
venous thrombosis (the collective term for DVT and PE), but anything
that makes blood ‘‘hypercoagulable’’ (prone to clotting) increases this
risk. Genetic risk factors can be inherited changes in blood clotting
proteins (for example, a mutation in a gene coding for one protein,
factor V, which is involved in clotting, is known as factor V Leiden—
Leiden, The Netherlands, was where it was first described). There are also
acquired risk factors such as taking oral contraceptives or being
immobilized (for example, during bed rest). These risk factors often act
in such a way that the risk of developing venous thrombosis for a person
with multiple risk factors is greater than the sum of the individual risks.
Another recently identified but little studied risk factor for venous
thrombosis is ‘‘hypofibrinolysis,’’ a decreased capacity to dissolve blood
clots. In this study (part of the ‘‘MEGA’’ study on risk factors for venous
thrombosis), the researchers investigate the combined effect of
hypofibrinolysis and established risk factors associated with hyper-
coagulability on the risk of developing venous thrombosis.
What Did the Researchers Do and Find? The researchers collected
blood from more than 2,000 individuals after their first DVT or PE and
from a similar number of persons without venous thrombosis (controls).
For each blood sample, they measured the time it took to dissolve a clot
generated from that blood in a test tube (the clot lysis time or CLT) and
determined which participants had the factor V Leiden mutation or a
genetic change in the clotting factor prothrombin that also increases
blood coagulability. The study participants also completed a question-
naire about acquired risk factors for venous thrombosis. The researchers
divided the participants into four equal-sized groups (quartiles) based on
their CLT and used the quartile with the lowest CLT as the reference
group for their statistical analyses; hypofibrinolysis was defined as a CLT
in the highest quartile (the longest times). Participants with hypofi-
brinolysis alone were twice as likely to develop venous thrombosis as
those with a CLT in the lowest quartile (the shortest times). Oral
contraceptive use alone increased the risk of venous thrombosis 2.5-fold,
whereas the combination of oral contraceptive use and hypofibrinolysis
increased the risk 20-fold. The researchers also found synergistic effects
on thrombosis risk for hypofibrinolysis combined with immobilization or
with the factor V Leiden mutation but not with the prothrombin
mutation.
What Do These Findings Mean? These findings confirm that persons
with hypofibrinolysis and hence longer CLTs have a greater risk of
developing venous thrombosis than those with short CLTs. Because CLTs
were measured after venous thrombosis had occurred, hypofibrinolysis
could be an effect rather than a cause of this condition. However, this is
unlikely because there was no association between how long after the
venous thrombosis the blood sample was taken and the measured CLT.
These findings also show that the combination of hypofibrinolysis with
immobilization, the factor V Leiden mutation, and oral contraceptive use
greatly increases the risk of venous thrombosis. This new information
about the risk factors for venous thrombosis should help physicians to
advise patients about reducing their chances of developing this life-
threatening condition.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050097.
 The MedlinePlus encyclopedia has pages on blood clots, deep vein
thrombosis, and pulmonary embolism (in English and Spanish)
 The US National Heart Lung and Blood Institute provides information
on deep vein thrombosis, including an animation about how DVT
causes pulmonary embolisms
 The UK National Health Service Direct health encyclopedia provides
information for patients on deep vein thrombosis (in several
languages)
 More information about the Multiple Environmental and Genetic
Assessment of risk factors for venous thrombosis (MEGA) study is
available on the Leiden University Medical Center Web site
 Wikipedia has pages on coagulation and on fibrinolysis (note that
Wikipedia is a free online encyclopedia that anyone can edit; available
in several languages)
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